S

StemRIM Inc
TSE:4599

Watchlist Manager
StemRIM Inc
TSE:4599
Watchlist
Price: 274 JPY 1.48% Market Closed
Market Cap: 17B JPY

StemRIM Inc
Investor Relations

StemRIM, Inc. engages in the research and development of regeneration inducing medicine. The company is headquartered in Ibaraki-Shi, Osaka-Fu and currently employs 46 full-time employees. The company went IPO on 2019-08-09. The firm is engaged in the development and research of medicines based on new action mechanism to promote functional regeneration and healing of biological tissue damaged and lost function due to injury or illness. The Company’s main product is stem cell regeneration-inducing medicine. The stem cell regeneration-inducing medicine is a medicine which can obtain the same therapeutic effect as regenerative medicine only by administering the medicine without using living cells and tissues.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Mr. Masatsune Okajima
President, CEO & Representative Director
No Bio Available
Mr. Katsuto Tamai
Chief Scientific Officer, Director of Basic Research Department & Director
No Bio Available
Mr. Takehiko Yamazaki
Head of Drug Discovery, Basic Research, R&D and Intellectual Prop., Dept. and Executive Officer
No Bio Available

Contacts

Address
OSAKA-FU
Ibaraki-shi
3F, Saito Bio-Incubator, 7-7-15, Saito Asagi
Contacts
+81726487152.0
stemrim.com